Basit öğe kaydını göster

dc.contributor.authorYılmaz, Ahmet
dc.contributor.authorHanlıoğlu, Selin
dc.contributor.authorDemiral, Gökhan
dc.contributor.authorKaratepe, Oğuzhan
dc.date.accessioned2023-12-24T17:39:38Z
dc.date.available2023-12-24T17:39:38Z
dc.date.issued2023en_US
dc.identifier.citationYilmaz, A., Hanlioğlu, S., Demiral, G., & Karatepe, O. (2023). The efficacy of liraglutide combined with intragastric balloon on weight loss. Revista da Associacao Medica Brasileira (1992), 69(12), e20230571. https://doi.org/10.1590/1806-9282.20230571en_US
dc.identifier.issn0104-4230
dc.identifier.issn1806-9282
dc.identifier.urihttps://doi.org/10.1590/1806-9282.20230571
dc.identifier.urihttps://hdl.handle.net/11436/8686
dc.description.abstractOBJECTIVE: Intragastric balloon placement is an effective method for weight reduction. The aim of this study was to evaluate the efficacy of combining liraglutide with intragastric balloon.METHODS: Initially, demographic data of patients such as age, gender, comorbid diseases, adverse events, initial weight, height, body mass index,percent body fat, and waist-hip ratio were collected. Weight, body mass index, percent body fat, and waist-hip ratio were measured in the second, third, fourth, fifth, and sixth months. Then, intragastric balloon was removed and liraglutide was stopped.RESULTS: A total of 50 patients were included in the study, of whom 28 (56%) were in Group A (intragastric balloon) and 22 (44%) were in Group B (plus liraglutide). Weight change at the time of balloon removal was higher in Group B [median weight change 13.8 (7.8 min to 16.8 max) versus 7.9 (4.8 min to 11.8 max); p<0.01]. When the weight, percent body fat, body mass index, and waist-hip ratio changes were compared according to gender, no significant difference was observed in the groups. Comorbid diseases were hypertension in 7 patients (4 in Group A and 3 in Group B) and diabetes in 9 patients (5 in Group A and 4 in Group B). No statistical significance was found.CONCLUSION: Liraglutide has benefits in terms of weight, percent body fat, and body mass index reduction when administered with intragastric balloon.en_US
dc.language.isoengen_US
dc.publisherAssoc Medica Brasileiraen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGlucagon-like peptide 1en_US
dc.subjectGastric balloonen_US
dc.subjectLiraglutideen_US
dc.subjectObesityen_US
dc.subjectBody weight changesen_US
dc.titleThe efficacy of liraglutide combined with intragastric balloon on weight lossen_US
dc.typearticleen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorDemiral, Gökhan
dc.identifier.doi10.1590/1806-9282.20230571en_US
dc.identifier.volume69en_US
dc.identifier.issue12en_US
dc.identifier.startpagee20230571en_US
dc.relation.journalRevista da Associacao Medica Brasileiraen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster